News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
822,469 Results
Type
Article (76049)
Company Profile (647)
Press Release (745773)
Multimedia
Podcasts (126)
Webinars (14)
Section
Business (228986)
Career Advice (3779)
Deals (39365)
Drug Delivery (129)
Drug Development (89667)
Employer Resources (198)
FDA (17910)
Job Trends (17171)
News (389887)
Policy (38939)
Tag
Academia (2999)
Academic (2)
Accelerated approval (6)
Adcomms (29)
Allergies (94)
Alliances (56301)
ALS (99)
Alzheimer's disease (1501)
Antibody-drug conjugate (ADC) (156)
Approvals (17875)
Artificial intelligence (303)
Autoimmune disease (28)
Automation (16)
Bankruptcy (403)
Best Places to Work (12633)
BIOSECURE Act (22)
Biosimilars (119)
Biotechnology (442)
Bladder cancer (85)
Brain cancer (32)
Breast cancer (301)
Cancer (2430)
Cardiovascular disease (204)
Career advice (3220)
Career pathing (34)
CAR-T (173)
Cell therapy (487)
Cervical cancer (21)
Clinical research (72410)
Collaboration (910)
Company closure (1)
Compensation (552)
Complete response letters (30)
COVID-19 (2866)
CRISPR (48)
C-suite (265)
Cystic fibrosis (107)
Data (2267)
Decentralized trials (2)
Denatured (44)
Depression (55)
Diabetes (297)
Diagnostics (6915)
Digital health (19)
Diversity (9)
Diversity, equity & inclusion (48)
Drug discovery (135)
Drug pricing (127)
Drug shortages (33)
Duchenne muscular dystrophy (101)
Earnings (94674)
Editorial (45)
Employer branding (25)
Employer resources (167)
Events (129220)
Executive appointments (773)
FDA (19239)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (8)
Funding (810)
Gene editing (119)
Generative AI (30)
Gene therapy (357)
GLP-1 (852)
Government (5130)
Grass and pollen (6)
Guidances (67)
Healthcare (20873)
Huntington's disease (25)
IgA nephropathy (31)
Immunology and inflammation (146)
Indications (30)
Infectious disease (3026)
Inflammatory bowel disease (153)
Inflation Reduction Act (11)
Influenza (56)
Intellectual property (101)
Interviews (741)
IPO (17748)
IRA (51)
Job creations (5025)
Job search strategy (2630)
Kidney cancer (11)
Labor market (42)
Layoffs (555)
Leadership (24)
Legal (9952)
Liver cancer (81)
Lung cancer (345)
Lymphoma (159)
Machine learning (7)
Management (65)
Manufacturing (346)
MASH (75)
Medical device (14619)
Medtech (14624)
Mergers & acquisitions (22160)
Metabolic disorders (788)
Multiple sclerosis (87)
NASH (23)
Neurodegenerative disease (114)
Neuropsychiatric disorders (34)
Neuroscience (2106)
NextGen: Class of 2025 (7639)
Non-profit (5082)
Now hiring (40)
Obesity (425)
Opinion (275)
Ovarian cancer (78)
Pain (99)
Pancreatic cancer (86)
Parkinson's disease (160)
Partnered (22)
Patents (250)
Patient recruitment (116)
Peanut (51)
People (64422)
Pharmaceutical (134)
Pharmacy benefit managers (21)
Phase I (22370)
Phase II (31554)
Phase III (23809)
Pipeline (1255)
Policy (172)
Postmarket research (3297)
Preclinical (9928)
Press Release (72)
Prostate cancer (113)
Psychedelics (38)
Radiopharmaceuticals (269)
Rare diseases (430)
Real estate (7199)
Recruiting (75)
Regulatory (26179)
Reports (57)
Research institute (2655)
Resumes & cover letters (589)
Rett syndrome (5)
RNA editing (5)
RSV (50)
Schizophrenia (81)
Series A (143)
Series B (91)
Service/supplier (27)
Sickle cell disease (58)
Special edition (18)
Spinal muscular atrophy (165)
Sponsored (34)
Startups (4210)
State (2)
Stomach cancer (16)
Supply chain (76)
Tariffs (46)
The Weekly (80)
Vaccines (813)
Venture capitalists (44)
Weight loss (304)
Women's health (39)
Worklife (20)
Date
Today (160)
Last 7 days (984)
Last 30 days (2824)
Last 365 days (35321)
2025 (11603)
2024 (37926)
2023 (42567)
2022 (53927)
2021 (58723)
2020 (57665)
2019 (51316)
2018 (39099)
2017 (36903)
2016 (37861)
2015 (43886)
2014 (38728)
2013 (34870)
2012 (36730)
2011 (36815)
2010 (36487)
Location
Africa (1204)
Alabama (60)
Alaska (7)
Arizona (251)
Arkansas (14)
Asia (48899)
Australia (8421)
California (6439)
Canada (2061)
China (563)
Colorado (284)
Connecticut (301)
Delaware (158)
Europe (110759)
Florida (942)
Georgia (220)
Hawaii (1)
Idaho (63)
Illinois (618)
India (30)
Indiana (333)
Iowa (12)
Japan (169)
Kansas (110)
Kentucky (28)
Louisiana (14)
Maine (70)
Maryland (969)
Massachusetts (4942)
Michigan (246)
Minnesota (420)
Mississippi (2)
Missouri (92)
Montana (31)
Nebraska (26)
Nevada (65)
New Hampshire (70)
New Jersey (1821)
New Mexico (31)
New York (1825)
North Carolina (1123)
North Dakota (9)
Northern California (2752)
Ohio (219)
Oklahoma (15)
Oregon (46)
Pennsylvania (1422)
Puerto Rico (13)
Rhode Island (36)
South America (1577)
South Carolina (24)
South Dakota (1)
Southern California (2384)
Tennessee (104)
Texas (956)
United States (24706)
Utah (191)
Virginia (170)
Washington D.C. (70)
Washington State (601)
West Virginia (3)
Wisconsin (68)
822,469 Results for "atom bioscience and pharmaceutical co ltd".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Atom Bioscience Marks Gout Awareness Day with Video Detailing Risks of Hyperuricemia, the Cause of Gout
Atom Bioscience, a clinical stage biotechnology company developing new treatments for metabolic and inflammatory diseases, such as gout, is calling for increased understanding of the dangers of chronic gout to help mark Gout Awareness Day, May 22, 2024.
May 21, 2024
·
2 min read
Press Releases
Merck Enters Exclusive License Agreement for HRS-5346, an Investigational Oral Lipoprotein(a) Inhibitor, for Cardiovascular Disease from Jiangsu Hengrui Pharmaceuticals Co., Ltd.
March 25, 2025
·
5 min read
Atom Bioscience Doses First Patient in Phase 2b/3 Clinical Trial of a New Treatment for Chronic Gout
Atom Bioscience (Jiangsu Atom Bioscience and Pharmaceutical Co., Ltd.), a clinical stage biotechnology company developing new treatments for inflammatory and metabolic diseases, announced today the first patient has been dosed in a Phase 2b/3
October 9, 2023
·
3 min read
Press Releases
WORK Medical Technology Group LTD Announces Strategic Partnership with Shanghai Chartwell Medical Device Co., Ltd.
March 3, 2025
·
5 min read
Press Releases
Oklo Closes Acquisition of Radioisotope Producer Atomic Alchemy
March 5, 2025
·
6 min read
Drug Development
Atom Bioscience Enrolling Patients in US as Part of a Global Phase 2b/3 Clinical Trial of a New Investigational Treatment for Chronic Gout
Atom Bioscience, a clinical stage biotechnology company developing new treatments for inflammatory and metabolic diseases, has begun enrolling patients in the US for in a Phase 2b/3 clinical trial of ABP-671, a novel investigational orally administered URAT1 inhibitor, for the treatment of chronic gout.
April 24, 2024
·
2 min read
Press Releases
Atom Therapeutics and China Medical System Holdings Enter Exclusive Commercialization Agreement for Lingdolinurad (ABP-671) to Treat Chronic Gout and Hyperuricemia
December 3, 2024
·
4 min read
Press Releases
BioCity Biopharmaceutics Co., Ltd. Announces Clinical Collaboration to Evaluate BC3195 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Locally Advanced or Metastatic Solid Tumors
March 13, 2025
·
3 min read
Press Releases
Lakeside Holding Enters Medical Logistics Sector with Acquisition of Hupan Pharmaceutical (Hubei) Co., Ltd.
November 11, 2024
·
4 min read
Business
Verrica Pharmaceuticals Announces Amendment to Company’s Collaboration and License Agreement with Torii Pharmaceutical Co. Ltd. to Fund Global Pivotal Phase 3 Clinical Trial to Study YCANTH® for the Treatment of Common Warts
Verrica Pharmaceuticals Inc. today announced that it has entered into an amendment to its existing licensing agreement with Torii Pharmaceutical Co. Ltd. (Torii), to jointly conduct a global pivotal Phase 3 clinical trial of YCANTH® for the treatment of common warts.
May 15, 2024
·
9 min read
1 of 82,247
Next
